Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro

Diabetes

Volumn 47, Issue 5, 1998, Pages 810-814

  Walker, Adrian B ^a,d   Naderali, Ebrahim K ^a   Chattington, Paula D ^b   Buckingham, Robin E ^c   Williams, Gareth ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ARTERY DIAMETER; ARTERY ENDOTHELIUM; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; HEMODILUTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN SENSITIVITY; PRIORITY JOURNAL; SKIN BLOOD FLOW;

ADIPOSE TISSUE; ANIMALS; ARTERIES; CHROMANS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 0031939168     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.5.810     Document Type: Article

References (36)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and with insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1118-1193, 1994
3. National Institutes of Health: Non-Insulin-Dependent Diabetes Primary Prevention Trial. NIH Guide Grants Contracts 22:1-20, 1993
4. Fujiwara T, Oshawa T, Miyamoto M, Ushiyama S, Matsuda K, Horikoshi H: Troglitazone (CS-045) acutely increases skin blood flow in dexamethasone-induced diabetic obese Zucker rats and normal rats (Abstract). Diabetes 44 (Suppl. 1):72A, 1995
5. Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK: Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
6. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1991
8. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 43:75-80, 1993
9. Kaufman LN, Peterson MM, DeGrange LM: Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44:1105-1109, 1995
10. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hseuh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
11. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of pioglitazone on calcium channels In vascular smooth muscle. Hypertension 24:170-175, 1994
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 270:12953-12956, 1995
13. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisome-proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinol 137:4189-4195, 1996
14. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouhchi S, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Baba S: An early phase II clinical trial of a new oral hypoglycemic drug, CS-045, in patients with non-insulin-dependent diabetes mellitus. J Clin Ther Med 9 (Suppl. 3):3-19, 1993
15. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin-dependent diabetes mellitus poorly controlled by diet alone: a dose-finding study by dose increasing method. J Clin Ther Med 9 (Suppl. 3):19-37, 1993
16. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin-dependent diabetes mellitus poorly controlled by sulphonylureas: a dose-finding study by dose increasing method. J Clin Ther Med 9 (Suppl 3):39-60, 1993
17. Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin-dependent diabetes mellitus poorly controlled by diet alone: a double-blind, placebo-controlled study. J Clin Ther Med 9 (Suppl. 3):61-93, 1993
18. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang Azen S, Buchanan TA: Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 45:1572-1579, 1996
19. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, the Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
20. Mulvany MJ, Halpern W: Mechanical properties of smooth muscle cells in situ. Nature 200:617-619, 1976
21. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive rats. Circ Res 41:19-26, 1977
22. 2+ currents and not endothelial nitric oxide production. Diabetes 46:659-664, 1997
23. Jaap AJ, Donohoe M, Shore AC, Tooke JE: Limited microvascular vasodilation in patients with acromegaly (Abstract). J Endocrinol 37 (Suppl.):45, 1993
24. Jaap AJ, Tooke JE: The pathophysiology of microvascular disease in non-insulin-dependent diabetes (Editorial). Clin Sci 89:3-12, 1995
25. Sandeman DD, Pym C, Green E, Seamark C, Shore AC, Tooke JE: Microvascular vasodilation In feet of newly-diagnosed non-insulin-dependent diabetic patients. BMJ 302:1122-1123, 1991
26. Baron AD: Hemodynamic actions of insulin. Am J Physiol 267:E187-E202, 1994
27. McNally PG, Lawrence IG, Watt PAC, Hillier C, Burden AC, Thurston H: The effect of insulin on the vascular reactivity of isolated resistance arteries taken from healthy volunteers. Diabetologia 38:467-473, 1995
28. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515, 1994
29. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179, 1994
30. Walker AB, Savage MW, Dores J, Williams G: Insulin-induced attenuation of noradrenaline-mediated vasoconstriction in resistance arteries from Wistar rats is nitric oxide dependent. Clin Sci 92:147-152, 1997
31. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 85:1844-1852, 1990
32. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skele tal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
33. Feldman RD, Briebier GS: Insulin-mediated vasodilatation: impairment with increased blood pressure and body mass. Lancet 342:707-709, 1993
34. Natali A, Quinones GA, Santoro D, Pecori N, Taddei S, Salvetti A, Ferrannini E: Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci 85:327-335, 1993
35. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL: Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 19:621-627, 1992
36. Canon JR, Eacho PI: Interaction of LY171883 and other peroxisome proliferators with fatty acid binding protein isolated from rat liver. Biochem J 280:387-391, 1991